• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

科威特风湿病学会 2018 年类风湿关节炎患者治疗建议。

Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis.

机构信息

Mubarak Al-Kabeer Hospital, Jabriya, Kuwait.

Al Jahra Hospital, Al Jahra, Kuwait.

出版信息

Rheumatol Int. 2019 Sep;39(9):1483-1497. doi: 10.1007/s00296-019-04372-y. Epub 2019 Jul 15.

DOI:10.1007/s00296-019-04372-y
PMID:31309293
Abstract

The Kuwait Association of Rheumatology (KAR) aimed to develop a set of recommendations for the treatment of patients with rheumatoid arthritis (RA), tailored to the unique patient population and healthcare system of Kuwait. Each recommendation was developed based on expert opinion and evaluation of clinical practice guidelines from other international and national rheumatology societies. Online surveys were conducted to collate feedback on each KAR member's level of agreement (LoA) with definitions of disease-/treatment-related terms used and the draft recommendations. Definitions/recommendations achieving a pre-defined cut-off value of ≥ 70% agreement were accepted for inclusion. Remaining statements were discussed and revised at a face-to-face meeting, with further modifications until consensus was reached. A final online survey was used to collect feedback on each KAR member's LoA with the final set of recommendation statements on a scale of 0 (complete disagreement) to 10 (complete agreement). Group consensus was achieved on 66 recommendation statements, including 3 overarching principles addressing the pharmacological treatment and management of RA. Recommendations focused on treatment of early RA, established RA, patients with high-risk comorbidities, women during pregnancy and breastfeeding, and screening and treatment of opportunistic infections. The KAR 2018 Treatment Recommendations for RA reported here are based on a synthesis of other national/international guidelines, supporting literature, and expert consensus considering the Kuwaiti healthcare system and RA patient population. These recommendations aim to inform the clinical decisions of rheumatologists treating patients in Kuwait, and to promote best practices, enhance alignment and improve the treatment experience for patients.

摘要

科威特风湿病学会 (KAR) 旨在制定一套针对类风湿关节炎 (RA) 患者的治疗建议,这些建议根据专家意见和对来自其他国际和国家风湿病学会的临床实践指南的评估,针对科威特独特的患者群体和医疗保健系统进行定制。

在线调查被用来收集每位 KAR 成员对用于疾病/治疗相关术语的定义以及草案建议的认同程度的反馈。达到预先定义的 ≥70% 认同度的定义/建议被接受纳入。其余的陈述在面对面会议上进行了讨论和修订,并进行了进一步的修改,直到达成共识。最后,使用在线调查收集每位 KAR 成员对最终建议陈述的认同程度的反馈,从 0(完全不同意)到 10(完全同意)进行评分。

在 66 项建议陈述上达成了共识,其中包括 3 项针对 RA 药物治疗和管理的总体原则。建议侧重于早期 RA、确诊 RA、有高风险合并症的患者、妊娠和哺乳期妇女以及机会性感染的筛查和治疗。

这里报告的 2018 年 KAR RA 治疗建议是基于对其他国家/国际指南、支持文献以及考虑到科威特医疗保健系统和 RA 患者群体的专家共识的综合。这些建议旨在为在科威特治疗患者的风湿病学家提供临床决策信息,并促进最佳实践、加强一致性和改善患者的治疗体验。

相似文献

1
Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis.科威特风湿病学会 2018 年类风湿关节炎患者治疗建议。
Rheumatol Int. 2019 Sep;39(9):1483-1497. doi: 10.1007/s00296-019-04372-y. Epub 2019 Jul 15.
2
2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.2016年更新的泰国风湿病协会关于类风湿关节炎患者使用生物制剂和靶向合成改善病情抗风湿药物的建议。
Int J Rheum Dis. 2017 Sep;20(9):1166-1184. doi: 10.1111/1756-185X.13130. Epub 2017 Jul 21.
3
Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association.非风湿病科医生类风湿关节炎诊断与管理的循证推荐:整合泰国风湿病协会的系统文献研究与专家意见
Int J Rheum Dis. 2017 Sep;20(9):1142-1165. doi: 10.1111/1756-185X.12905. Epub 2016 Jul 25.
4
2018 update of the APLAR recommendations for treatment of rheumatoid arthritis.《亚太风湿病学联盟类风湿关节炎治疗推荐(2018年更新版)》
Int J Rheum Dis. 2019 Mar;22(3):357-375. doi: 10.1111/1756-185X.13513. Epub 2019 Feb 27.
5
Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.加拿大风湿病学会关于传统和生物改善病情抗风湿药物治疗类风湿关节炎的药物治疗建议:第二部分安全性。
J Rheumatol. 2012 Aug;39(8):1583-602. doi: 10.3899/jrheum.120165. Epub 2012 Jun 15.
6
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.2015年美国风湿病学会类风湿关节炎治疗指南
Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. Epub 2015 Nov 6.
7
Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.加拿大风湿病学会关于传统和生物改善病情抗风湿药物治疗类风湿关节炎的药物治疗建议。
J Rheumatol. 2012 Aug;39(8):1559-82. doi: 10.3899/jrheum.110207. Epub 2011 Sep 15.
8
Using a modified Delphi process to establish clinical consensus for the diagnosis, risk assessment and abatacept treatment in patients with aggressive rheumatoid arthritis.采用改良的德尔菲法,就侵袭性类风湿关节炎患者的诊断、风险评估及阿巴西普治疗达成临床共识。
Clin Exp Rheumatol. 2017 Sep-Oct;35(5):772-776. Epub 2017 Mar 3.
9
Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative.类风湿关节炎、银屑病和银屑病关节炎合并症管理的循证推荐:加拿大皮肤病学-风湿病学合并症倡议专家意见
J Rheumatol. 2015 Oct;42(10):1767-80. doi: 10.3899/jrheum.141112. Epub 2015 Jul 15.
10
Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology.类风湿关节炎的管理:香港风湿病学会 2019 年更新的共识建议。
Clin Rheumatol. 2019 Dec;38(12):3331-3350. doi: 10.1007/s10067-019-04761-5. Epub 2019 Sep 4.

引用本文的文献

1
What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines.类风湿关节炎治疗的核心推荐有哪些?临床实践指南的系统评价。
Clin Rheumatol. 2023 Sep;42(9):2267-2278. doi: 10.1007/s10067-023-06654-0. Epub 2023 Jun 9.
2
Consistency of recommendations for pharmacotherapy of rheumatoid arthritis.类风湿关节炎药物治疗建议的一致性。
Front Pharmacol. 2022 Oct 25;13:967787. doi: 10.3389/fphar.2022.967787. eCollection 2022.
3
The burden of rheumatoid arthritis in the Middle East and North Africa region, 1990-2019.

本文引用的文献

1
The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.JAK1/JAK2 抑制在类风湿关节炎中的作用:巴瑞替尼的疗效和安全性。
Clin Exp Rheumatol. 2019 Jul-Aug;37(4):694-704. Epub 2019 Feb 11.
2
The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.甲氨蝶呤与其他改善病情抗风湿药物对肿瘤坏死因子抑制剂治疗类风湿关节炎患者血清药物水平和临床反应的影响。
Clin Rheumatol. 2019 Mar;38(3):949-954. doi: 10.1007/s10067-018-4355-0. Epub 2018 Nov 6.
3
1990 年至 2019 年期间中东和北非地区类风湿性关节炎的负担。
Sci Rep. 2022 Nov 11;12(1):19297. doi: 10.1038/s41598-022-22310-0.
4
Protein DEK and DTA Aptamers: Insight Into the Interaction Mechanisms and the Computational Aptamer Design.蛋白质DEK与DTA适体:对相互作用机制及适体计算设计的深入了解
Front Mol Biosci. 2022 Jul 19;9:946480. doi: 10.3389/fmolb.2022.946480. eCollection 2022.
5
Effectiveness and safety of aerobic exercise for rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.有氧运动对类风湿关节炎的有效性和安全性:一项随机对照试验的系统评价和荟萃分析
BMC Sports Sci Med Rehabil. 2022 Feb 5;14(1):17. doi: 10.1186/s13102-022-00408-2.
6
A Review of the Prevalence and Unmet Needs in the Management of Rheumatoid Arthritis in Africa and the Middle East.非洲和中东地区类风湿关节炎管理的患病率及未满足需求综述
Rheumatol Ther. 2021 Mar;8(1):1-16. doi: 10.1007/s40744-020-00252-1. Epub 2020 Nov 23.
7
Accessibility to biologics and its impact on disease activity and quality of life in patients with rheumatoid arthritis in Kuwait.科威特类风湿关节炎患者使用生物制剂的可及性及其对疾病活动度和生活质量的影响。
Clin Rheumatol. 2021 May;40(5):1759-1765. doi: 10.1007/s10067-020-05444-2. Epub 2020 Oct 12.
Diagnosis and Management of Rheumatoid Arthritis: A Review.
类风湿关节炎的诊断与治疗:综述。
JAMA. 2018 Oct 2;320(13):1360-1372. doi: 10.1001/jama.2018.13103.
4
Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review.生物制剂类改善病情抗风湿药物对类风湿关节炎放射学进展的影响:系统文献回顾。
Clin Exp Rheumatol. 2018 Jul-Aug;36(4):658-667. Epub 2018 Mar 20.
5
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.慢性乙型肝炎的预防、诊断和治疗最新进展:美国肝病研究学会2018年乙型肝炎指南
Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800.
6
Treatment with Biologicals in Rheumatoid Arthritis: An Overview.类风湿关节炎的生物制剂治疗:综述
Rheumatol Ther. 2017 Dec;4(2):247-261. doi: 10.1007/s40744-017-0073-3. Epub 2017 Aug 22.
7
Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.巴瑞替尼治疗类风湿关节炎患者的安全性和疗效:一项开放标签、长期扩展研究的 128 周结果。
J Rheumatol. 2018 Jan;45(1):14-21. doi: 10.3899/jrheum.161161. Epub 2017 Aug 15.
8
Biosimilars: implications for rheumatoid arthritis therapy.生物类似药:对类风湿关节炎治疗的影响。
Curr Opin Rheumatol. 2017 May;29(3):260-268. doi: 10.1097/BOR.0000000000000379.
9
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.EULAR 推荐的类风湿关节炎治疗策略:2016 年更新版
Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6.
10
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.托法替布治疗类风湿关节炎长达8.5年的长期安全性:来自全球临床试验数据的综合分析
Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.